Gefapixant (Lyfnua; Merck & Co.) is a first-in-class, non-narcotic, selective P2X3 receptor antagonist being developed for the treatment of refractory chronic cough or unexplained chronic cough. Marketing approval for gefapixant is being sought in the EU and USA, and the drug was recently approved for marketing in Japan as treatment for refractory or unexplained chronic cough. This article summarizes the milestones in the development of gefapixant leading to this first approval.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-022-01700-8 | DOI Listing |
Publication Analysis
Top Keywords
chronic cough
12
approval gefapixant
8
treatment refractory
8
unexplained chronic
8
gefapixant
4
gefapixant approval
4
gefapixant lyfnua
4
lyfnua merck
4
merck first-in-class
4
first-in-class non-narcotic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!